The newspaper “El Periódico” interviews Meritxell Teixidó, associate researcher at IRB Barcelona, and Benjamí Oller Salvia, former PhD student at the same institute, about their research performed in the Design, Synthesis and Structure of Peptides and Proteins Lab. In the article, they talk about their discovery, namely a shuttle capable of transporting molecules into the brain.
Link to El Periódico
The youngest and most restless scientists often keep themselves busy with projects outside their labs. One such project is the "Scientists Dating Forum," which has attracted the interest of several PhD students at IRB Barcelona.
In vivo met Yoran Beldengrün, a Swiss PhD student at the Institute for Advanced Chemistry of Catalonia – CSIC, who is behind the initiative in which more than 50 people—including scientists, journalists, artists, and entrepreneurs—have been actively involved since the beginning of the year.
“I noticed that many people were...
The biotech will set aside this injection of capital –led by Caixa Capital Risc- to complete the preclinical phase in order to start Human Phase I trials of its compound to the treatment of Cognitive Impairment Associated with Schizophrenia. The drug is one of the few under development worldwide to halt the progression and reverse the symptoms of this condition.
The drug is a first-in-class for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS). The compound has been developed using their proprietary IPROTech, a cutting-edge platform the fast and cost-effectively obtaining of innovative drugs.
Iproteos, settled at the Parc Cientific de Barcelona, is a spin-off created in 2011 by two Catalan leading scientists in the field of therapeutic peptides, Teresa Tarragó and Ernest Giralt, based on the technology transfer from IRB Barcelona and the University of Barcelona.
Back from a very rewarding stay in Yale, Pol already has new ideas in mind to overcome the barrier that protects the brain and makes it so difficult to design drugs to cure neurological diseases.
IRB Barcelona and the Graduate School of Pharmaceutical Sciences of the Tohoku University in Japan have signed a new academic exchange agreement. In August, the Dean of the Japanese institution and IRB Barcelona Director Joan J. Guinovart endorsed a long-standing collaboration between scientists at the two centres.
Extensive impact of Natàlia Carulla’s work at IRB Barcelona on a new method through which to study neuron death in Alzheimer’s disease.
Published in PNAS, the study addresses the effects of an amyloid protein aggregate that has the capacity to perforate the neuronal cell membrane—a process that may cause the toxicity of these aggregates and that could be validated as a therapeutic target.
Link to La Vanguardia:
Researchers at IRB Barcelona describe for the first time how to prepare a specific type of aggregate of the amyloid-beta protein with the ability to perforate the cell membrane.
What causes neuron death and the subsequent cognitive decline in Alzheimer´s disease is still unknown.
IRB Barcelona researchers publish a review article on the emerging field of drug transporters that have the capacity to reach the brain more efficiently.
IRB Barcelona is one of the few centres worldwide with a specific line of research devoted to this field, which brings together chemistry, pharmacy and biomedicine.
The article appears on the cover of the journal Chemical Society Reviews.
“I’m still enthusiastic. Just a bit less naïve.” Salva Guardiola, PhD student in Ernest Giralt’s Design, Synthesis, and Structure of Peptide and Proteins Lab, has just published his first paper in ChemBioChem. And in the life of a researcher, the first article is never forgotten, it leaves a mark the rest of your career.
The idea Salva and his colleagues had was to design and test a peptide,...
The medical portal ""El Médico Hospitaliario" and other media report on IRB Barcelona's research on compounds able to act against EGF, a little-explored cancer target.
The study has been published in ChemBioChem.